InvestorsHub Logo
Followers 840
Posts 120472
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Thursday, 11/05/2020 8:24:41 AM

Thursday, November 05, 2020 8:24:41 AM

Post# of 875
MRK acquires—(private)—VelosBio_for_$2.75B cash:

https://www.businesswire.com/news/home/20201105005543/en

VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News